Mylan/Aventis Terminate Zagam Deal; Mylan Clears Books Of Pending Suits
Executive Summary
Mylan and Aventis are ending the Zagam marketing deal under a settlement of claims arising from supply problems with the antibiotic
You may also be interested in...
BuSpar Antitrust Settlement Is Two-Times Sales During Extended Patent Life
Bristol-Myers Squibb's proposed $535 mil. payment to settle BuSpar antitrust litigation amounts to more than twice the sales of the anxiety drug during the four months of extended exclusivity for the product that prompted the suits
Mylan Zagam
Mylan "has indicated that they are presently marketing the antibiotic Zagam and it remains a part of their Bertek branded product line," the company stated Feb. 16. The generics manufacturer previously indicated that it was discontinuing Zagam (1"The Pink Sheet" Feb. 5, p. 29). Mylan said it wrote down $3.6 mil. of the Zagam (sparfloxacin) product license in its Jan. 30 third quarter report because of "supply issues," and that it "continues to work to try to resolve the issues surrounding Zagam"
Mylan Must Give FTC 30-Day Notice Before Any Exclusive Bulk Agreement
Mylan has to give the Federal Trade Commission 30-day advance notice for any exclusive agreements dealing with active pharmaceutical ingredients under a Nov. 29 consent decree.